Corona Remedies

What Corona Remedies does

Corona Remedies Limited is an India-based pharmaceutical formulations company headquartered in Ahmedabad, Gujarat, founded in 2004 by Nirav K. Mehta and Ankur K. Mehta. The company manufactures and markets branded generic pharmaceutical formulations across four primary therapeutic areas: women's healthcare (rank #5), cardio-diabetes (rank #21), pain management (rank #5), and urology (rank #9), with additional presence in anti-infectives, gastroenterology, and respiratory segments. Products span ten drug delivery systems including tablets, capsules, powders, liquids, and injectables, produced across two WHO-GMP certified manufacturing facilities in Bhayla (Gujarat, also EU-GMP and EAEU-GMP certified) and Solan (Himachal Pradesh), with a third hormonal manufacturing facility under development in Gujarat. The company employs 5,600+ people including 700+ in manufacturing and operates 11 production lines.

The company's commercial model centers on a 'tail brand' acquisition strategy: acquiring underpenetrated or divested brands from multinational pharmaceutical companies and scaling them through Corona's distribution network. Since 2016, the company has acquired brands from GlaxoSmithKline (Vitneurin, Stelbid, Dilo DX, Dilo BM), Abbott India (Obimet, Thyrocab), Sanofi (Myoril), Bayer Zydus Pharma (NOKLOT, Fostine, Luprofact, Menodac, Ovidac, Spye, Vageston), and Dr. Reddy's Laboratories (Wokadine). Internally developed brands include GB-29 (ranked #8 in neuropathic pain), COR-3 (ranked #1 in women's healthcare), DOSIN (74% CAGR in urology), CORTEL, and ROSULESS. The company also holds semi-exclusive and exclusive marketing rights for women's healthcare and urology products through a partnership with Switzerland-based Ferring Pharmaceuticals.

Revenue is generated primarily through domestic branded formulation sales via a network of 5,000+ carrying and forwarding agents and distributors serving specialist and super-specialist doctors in urban and semi-urban India, supplemented by international sales across 20 countries through local marketing collaborations in the UAE, Philippines, Kenya, Cyprus, and Uzbekistan. The company is publicly listed on NSE and BSE following its December 2025 IPO, which was subscribed 137.04 times at a market capitalization of approximately ₹6,495 crore. FY26 revenue reached ₹1,403.18 crore (up 17.28% YoY) with adjusted PAT of ₹199.42 crore, making Corona the second-fastest growing company among the top 30 in the Indian Pharmaceutical Market with a CAGR of 19% versus the IPM's 9%.

Name

Corona Remedies

Legal name

CORONA Remedies Limited

Website

https://coronaremedies.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Corona Remedies is an Indian branded-generic pharmaceutical formulations manufacturer headquartered in Ahmedabad, founded in 2004 and listed on NSE/BSE since December 2025. The company serves specialist doctors in women's healthcare, cardio-diabetes, pain management, and urology through a 5,000+ C&F distribution network, manufacturing products at two WHO-GMP certified facilities in Gujarat and Himachal Pradesh with FY26 revenue of ₹1,403.18 crore.

Ownership category

akta.pro rank

Product category

Pharmaceutical Formulations

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Pharmaceutical formulations
• Branded generic medicines
• Chronic disease therapeutics
• Women's health medications
• Urology pharmaceuticals

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales (Domestic Formulations): Revenue from sale of branded pharmaceutical formulations across key therapeutic areas in the domestic Indian market, including women's healthcare, cardio-diabetes, pain management, and urology. Products sold through field force and distribution network to healthcare providers.
2. International Product Sales: Revenue from international markets including UAE, Philippines, Kenya, Cyprus, and Uzbekistan through product registrations and marketing collaborations with local partners.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Corona Remedies is an Indian pharmaceutical formulations manufacturer that develops, produces, and markets branded generic medicines across multiple drug delivery systems including tablets, capsules, powders, liquids, and injectables. The company's portfolio is concentrated in four therapeutic areas—women's healthcare, cardio-diabetes, pain management, and urology—and is built through a combination of in-house brand development (GB-29, COR-3, CORTEL, ROSULESS, TRICIUM, DOSIN) and acquisition of underpenetrated brands from multinational pharmaceutical corporations (MYORIL from Sanofi, OBIMET from Abbott, NOKLOT and six women's health brands from Bayer, Wokadine from Dr. Reddy's). Products are sold through a domestic network of 5,000+ C&F agents and distributors supported by a field force targeting specialist doctors, and through local marketing partners in 20 international markets.

Product overview

Corona Remedies is a Gujarat-based pharmaceutical company operating as a formulations manufacturer with a focused portfolio strategy across four key therapeutic areas: Women's Healthcare (#5 market rank), Cardio-Diabetes (#21 rank), Pain Management (#5 rank), and Urology (#9 rank). The company operates two WHO-GMP certified manufacturing facilities (Gujarat with EU-GMP certification, Himachal Pradesh) and is establishing a hormone manufacturing facility. Corona's product strategy combines organic brand development (GB-29, COR-3, CORTEL, ROSULESS, TRICIUM, DOSIN) with strategic brand acquisitions from multinationals (MYORIL from Sanofi, OBIMET from Abbott, Wokadine from Dr. Reddy's, 7 brands including NOKLOT from Bayer). The company also holds semi-exclusive rights to women's healthcare and urology products through partnership with Ferring Pharmaceuticals. Recent launches include entry into the infertility segment (2026) and new products like Tricium Joints and Fostine R.

Differentiator

Problem solved

Functional benefit

Brands

• B-29: Vitamin B complex brand for neuropathy management and general supplementation
• Myoril
• Tricium
• Cortel
• Obimet
• COR-3
• Dydrohope
• GB-29
• DOSIN
• Wokadine

Products and services

• GB-29 (B-29) Pregabalin and methylcobalamin combination brand indicated for the management of diabetic neuropathy pain; a core neuropathic pain brand for Corona with multiple line extensions (Plus, Total, SR, Semi, D).
• MYORIL Thiocolchicoside-based brand indicated for the treatment of musculoskeletal spasms; acquired from Sanofi in 2023 and scaled with strong brand equity in the orthopedics segment.
• COR-3 Women's health formulation containing L-Methylfolate, Methylcobalamin, and Pyridoxal-5-phosphate; ranked #1 in its market within women's healthcare.
• CORTEL Telmisartan-based cardiovascular brand available in multiple combinations (with Cilnidipine, Amlodipine, Chlorthalidone, Hydrochlorothiazide, Metoprolol); fast-growing with 13% CAGR in domestic sales.
• ROSULESS Rosuvastatin-based cardiovascular brand with multiple combinations (Ez, A, C, F, Gold); fast-growing brand with 30% CAGR in domestic sales.
• OBIMET Metformin-based anti-diabetic brand acquired from Abbott India in 2017; available in multiple formulations including OBIMET GX, OBIMET SR, and Triobimet for cardio-diabetes segment.
• TRICIUM Calcium supplement brand with Calcium Citrate Malate and Vitamin D3 formulation; multiple variants including Tricium XT, Active, HD, Max, Plus, and PTH PF.
• DOSIN Silodosin-based brand for benign prostatic hyperplasia (BPH); ranked 4th in its covered market with 74% CAGR per Pharmatrac MAT Dec'25.
• Wokadine Povidone-iodine antiseptic brand acquired from Dr. Reddy's Laboratories for approximately Rs 648 crore, providing entry into India's Rs 648 crore povidone iodine market for wound care and anti-infective segments.
• NOKLOT Cardiology brand (clopidogrel) acquired from Bayer Zydus Pharma in July 2025 as part of a 7-brand acquisition, strengthening Corona's cardiology segment position.
• Fostine, Luprofact, Menodac, Ovidac, Spye, Vageston Women's healthcare brands acquired from Bayer Zydus Pharma in July 2025, strengthening Corona's gynaecology and infertility portfolio for the Indian market.
• Tricium Joints Combination supplement for joint health containing Sodium, Collagen Type II, Vitamin D3, Calcium Citrate Maleate, Magnesium, Zinc, Manganese, Copper, and Vitamin C; a Tricium line extension for joint health.
• Fostine R Recombinant Follicle Stimulating Hormone Alpha Prefilled Pen for fertility treatment; part of Corona's women's healthcare portfolio expansion.
• Florapill Probiotic capsule containing Lactobacillus plantarum PBS067, Lactobacillus rhamnosus LRH20, Bifidobacterium lactis BL050, and Chicory root powder for gut health.

Quantifiable outcome

• Revenue grew from ₹884 crore (FY23) to ₹1,403 crore (FY26), CAGR of ~19% vs IPM CAGR of 9%; 17.28% YoY revenue growth in FY26
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered minor, core and strategic.

• Dr. Reddy's LaboratoriesminorOthers · 30 March 2026Corona Remedies acquired the Wokadine brand from Dr. Reddy's Laboratories for approximately ₹648 crore, effective March 30, 2026. The acquisition grants entry into India's ₹648 crore povidone iodine market and is Corona's fifth acquisition from a multinational corporation. Fully funded through internal accruals.
• Bayer Zydus Pharma Private LimitedcoreOthers · 16 July 2025CORONA acquired 7 brands from the pharmaceutical division of Bayer in India in July 2025, including cardiology brand NOKLOT and women's healthcare brands FOSTINE, LUPROFACT, MENODAC, OVIDAC, SPYE, and VAGESTON. This strategic step strengthens positions in both cardiology and women's healthcare segments.
• Sanofi Healthcare India Private LimitedstrategicOthers · 1 January 2024CORONA acquired the Myoril brand (thiocolchicoside) from Sanofi in FY2024, strengthening the pain management portfolio. The brand has been significantly scaled since acquisition with strong brand equity built in orthopedics.
• Ferring PharmaceuticalscoreStrategic or Co-development Partner · 13 September 2022CORONA Remedies entered into an agreement with Ferring Pharmaceuticals Pvt. Ltd., a subsidiary of Switzerland-based Ferring Pharmaceuticals, granting semi-exclusive and exclusive rights to market certain products across women's healthcare and urology therapeutic areas in India. This strategic partnership strengthens gynaecology and urology portfolios.
• La Chandra PharmalabstrategicStrategic or Co-development Partner · 1 January 2020Strategic alliance with La Chandra Pharmalab, an emerging API manufacturing company with EU-GMP approvals for various APIs. The partnership secures API supply chain and supports manufacturing quality standards for both Indian and European markets.
• Abbott India LimitedstrategicOthers · 1 January 2018CORONA acquired the Obimet and Thyrocab range of brands from Abbott India, strengthening presence in diabetes (Obimet) and thyroid management (Thyrocab) therapeutic areas.
• GlaxoSmithKline (GSK)minorOthers · 1 January 2016CORONA acquired Vitneurin, Stelbid, Dilo DX, and Dilo BM from GlaxoSmithKline, consolidating positions in the nutraceuticals, respiratory, and gastroenterology therapeutic areas.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Mankind Pharma: Mankind Pharma is one of India's largest domestic-focused pharmaceutical companies with a strong presence in chronic and acute therapy areas including cardiology, diabetes, and women's health. Both companies compete in the Indian branded generics market with similar specialist-doctor field force models and therapy area focus.
• Ajanta Pharma: Ajanta Pharma is an Indian specialty formulations company with focus on cardiology, dermatology, and ophthalmology segments. Both companies serve specialist doctors with branded generics and have meaningful international presence via partner-led models in semi-regulated markets.
• Strides Pharma: Strides Pharma is an Indian pharmaceutical company with global presence in specialty generics including women's health, anti-infectives, and chronic disease therapies. Comparable to CORONA in formulations manufacturing scale and women's health portfolio focus.
• JB Chemicals & Pharmaceuticals: JB Chemicals is a mid-sized Indian pharmaceutical formulations company with a portfolio spanning cardiology, anti-infectives, and gastroenterology. The companies share similar scale, Indian market focus, and branded generics strategy targeting specialist and GP channels.
• Ipca Laboratories: Ipca Laboratories is a mid-sized Indian pharmaceutical company with a domestic formulations portfolio and active pharmaceutical ingredient manufacturing. Both companies compete in domestic chronic disease therapy markets while operating API/international strategies.
• Eris Lifesciences: Eris Lifesciences is an Indian specialty pharmaceutical company focused on chronic disease segments including cardio-diabetes, women's health, and CNS. Like CORONA, Eris uses a strategy of acquiring niche brands and targeting specialist doctors, making it a direct comparable in business model and therapeutic focus.
• Alembic Pharmaceuticals: Alembic Pharmaceuticals is an Indian formulations and API manufacturer with focus on cardiology, anti-infectives, and gynecology. Both companies share a similar mid-cap scale, Indian market focus, and specialty therapy orientation.
• Natco Pharma: Natco Pharma is an Indian specialty pharmaceutical company focused on oncology, cardiology, and niche therapy areas with both domestic and international operations. While oncology-led, Natco shares CORONA's strategy of targeting specialist segments with branded formulations in chronic disease categories.

Broad incumbents

• Torrent Pharmaceuticals: Torrent Pharmaceuticals is a larger Indian pharma company with significant presence in cardio-diabetes, CNS, and gastroenterology segments. While substantially bigger, Torrent shares CORONA's focus on chronic therapy areas and specialist-driven prescription generation in India.
• Cadila Healthcare (Zydus): Zydus is one of India's largest integrated pharmaceutical companies with broad presence across formulations, APIs, biologics, and consumer health. As a larger incumbent, Zydus represents the scale benchmark CORONA is targeting, with overlapping therapy areas in women's health, cardiology, and pain management.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/corona-remedies

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corona Remedies